menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Even after Prometheus, Acceleron deals, Merck primed for M&A

    FIERCE PHARMA

    Merck unwraps full PIII data on the centerpiece from its $11.5B Acceleron buyout

    ENDPTS

    Early look at how Merck & Co.’s sotatercept could impact PAH space

    FIRSTWORLDPHARMA

    Merck nails phase 3 sotatercept win a year after acquiring it

    FIERCEBIOTECH

    Celgene, Acceleron alum Backstrom tapped to lead Scholar Rock

    FIERCEBIOTECH

    FDA warns small biotech Ocugen of potential $10K fines for failing

    ENDPTS

    Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA

    BIOSPACE

    Merck fights off Acceleron`s activist investors

    FIERCEPHARMA

    Merck Completes Tender Offer to Acquire Acceleron Pharma

    FIRSTWORLFPHARMA

    Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.

    BUSINESSWIRE

    Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period

    BUSINESSWIRE

    Avoro Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer

    BUSINESSWIRE

    Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders

    BUSINESSWIRE

    Another Acceleron investor challenges Merck deal

    FIERCEPHARMA

    Merck refiles Acceleron deal with the FTC

    FIERCEPHARMA

    Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act

    BUSINESSWIRE

    Merck set to deploy millions of Covid antiviral pills if regulators approve: CEO

    CNBC

    Ahead of closing $11.5B Acceleron buyout, Merck is on the hunt for more deals

    ENDPTS

    BMS Buyout Rumors Send Canadian Biopharma’s Stock Soaring

    BIOSPACE

    BMS, after weighing Acceleron buy, now eyes Aurinia: Bloomberg

    FIERCEPHARMA

    Activist investor asks Merck to double Acceleron offer

    FIERCEPHARMA

    Hedge fund jumps in with Avoro activists to derail Merck`s $11B Acceleron buyout

    ENDPTS

    Bristol-Myers Plans to Exit Acceleron Stake With Merck Deal

    BNNBLOOMBRG

    Merck started its Acceleron pursuit at $10.2B, ended at $11.5

    FIERCEPHARMA

    Biogen, Mirati, mRNA players on Merck`s M&A shortlist: FT

    FIERCEPHARMA

    Activist investor revolts against Acceleron`s $11.5B sale

    FIERCEPHARMA

    Acceleron falls below averages, but Avoro looks opportunistic

    EVALUATE

    Unexpected win opens the way to an oral Covid antiviral

    EVALUATE

    Merck buys Acceleron for $11.5B, dowplays antitrust threat

    FIERCEPHARMA

    Merck & Co justifies paying up for Acceleron

    EVALUATE

    Merck`s reported $11B Acceleron buy could face antitrust hurdles

    FIERCEPHARMA

    Merck emerges as lead bidder in potential Acceleron buyout — report

    ENDPTS

    Mystery suitor lines up $11B Acceleron acquisition: report

    FIERCEBIOTECH

    Rumors suggest that Acceleron is in advanced buyout talks: Report

    ENDPTS

    Acceleron Reports Second Quarter 2021 Financial Results

    BUSINESSWIRE

    Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales

    BUSINESSWIRE

    Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021

    BUSINESSWIRE

    BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients

    PMLIVE

    Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021

    BUSINESSWIRE

    Acceleron, under threat of fines, reports out a negative study

    RAPS

    Acceleron Presents Preliminary Data from the SPECTRA Ph 2 Trial of Sotatercept

    BIOSPACE

    Acceleron Presents Interim Results from the Open-label Extension the PULSAR Ph2

    BUSINESSWIRE

    Acceleron Presents Preliminary Data from the SPECTRA Ph2 Trial of Sotatercept

    BUSINESSWIRE

    Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates

    BUSINESSWIRE

    Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates

    BUSINESSWIRE

    FDA Gets Tough on Sponsors Not Reporting Clinical Trial Results

    PHARMTECH

    FDA gives first citation to biotech for failure to report clinical trial details

    BIOPHARMADIVE

    In a first, FDA issues a serious rebuke for trial data delay

    FIERCE BIOTECH

    FDA warns Acceleron of possible fines for not posting results from failed trial

    ENDPTS

    Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales

    BUSINESSWIRE

    EC grants orphan status to Acceleron’s sotatercept to treat PAH

    PHARMABIZ

    Acceleron Receives Orphan Designation from the (EC) for Sotatercept

    BUSINESSWIRE

    Acceleron Receives Orphan Designation from the (EC) for Sotatercept

    BUSINESSWIRE

    Acceleron Receives FDA Orphan Drug Designation for ACE-1334

    BUSINESSWIRE

    Acceleron Presents New Data from the PULSAR Phase 2 Trial

    BUSINESSWIRE

    Acceleron Announces Clinical Trial Updates, Preclinical on Sotatercept

    BIOSPACE

    Acceleron Announces Clinical Trial , Preclinical Presentation on Sotatercept

    BUSINESSWIRE

    Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations

    BUSINESSWIRE

    Health Canada Approves REBLOZYL® (luspatercept)

    BUSINESSWIRE

    Two Rare Disease Focused Biotechs Raise $900 Million in Follow-on Offerings

    GLOBALNEWS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.